1. Home
  2. CMU vs IMAB Comparison

CMU vs IMAB Comparison

Compare CMU & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMU
  • IMAB
  • Stock Information
  • Founded
  • CMU 1987
  • IMAB 2014
  • Country
  • CMU United States
  • IMAB United States
  • Employees
  • CMU N/A
  • IMAB N/A
  • Industry
  • CMU Investment Managers
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMU Finance
  • IMAB Health Care
  • Exchange
  • CMU Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • CMU 89.6M
  • IMAB 87.2M
  • IPO Year
  • CMU N/A
  • IMAB 2020
  • Fundamental
  • Price
  • CMU $3.55
  • IMAB $0.99
  • Analyst Decision
  • CMU
  • IMAB Strong Buy
  • Analyst Count
  • CMU 0
  • IMAB 3
  • Target Price
  • CMU N/A
  • IMAB $8.00
  • AVG Volume (30 Days)
  • CMU 82.4K
  • IMAB 274.1K
  • Earning Date
  • CMU 01-01-0001
  • IMAB 03-13-2025
  • Dividend Yield
  • CMU 4.08%
  • IMAB N/A
  • EPS Growth
  • CMU N/A
  • IMAB N/A
  • EPS
  • CMU 0.07
  • IMAB N/A
  • Revenue
  • CMU N/A
  • IMAB $3,313,984.00
  • Revenue This Year
  • CMU N/A
  • IMAB N/A
  • Revenue Next Year
  • CMU N/A
  • IMAB N/A
  • P/E Ratio
  • CMU $47.57
  • IMAB N/A
  • Revenue Growth
  • CMU N/A
  • IMAB N/A
  • 52 Week Low
  • CMU $2.78
  • IMAB $0.84
  • 52 Week High
  • CMU $3.38
  • IMAB $2.08
  • Technical
  • Relative Strength Index (RSI)
  • CMU 55.53
  • IMAB 43.19
  • Support Level
  • CMU $3.50
  • IMAB $1.03
  • Resistance Level
  • CMU $3.58
  • IMAB $1.10
  • Average True Range (ATR)
  • CMU 0.02
  • IMAB 0.06
  • MACD
  • CMU 0.01
  • IMAB -0.01
  • Stochastic Oscillator
  • CMU 66.67
  • IMAB 7.58

About CMU MFS Municipal Income Trust

Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: